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ABSTRACT  
Aim: To assess interobserver variation in reporting nuclear features of encapsulated follicular 
variant of papillary thyroid carcinoma, newly reclassified as non-invasive follicular thyroid 
neoplasm with papillary-like nuclear features (NIFTP), based on a proposed standardized scoring 
system.  
Methods: An education module was individually reviewed as a pre-evaluation teaching guide of 
the specific features of classical papillary carcinoma, the specific inclusion and exclusion 
features for the diagnosis of NIFTP, and a catalogue of the standardized scoring system of the 
nuclear features of papillary carcinoma used to reach this diagnosis. Participants subsequently 
reviewed 30 cases of thyroid lesions previously scored by members of the Endocrine Pathology 
Society Working Group for the Re-evaluation of the Encapsulated Follicular Variant of Papillary 
Thyroid Carcinoma. There was one uninvolved reference image to demonstrate fixation, 
processing and cell size and one image from each case for scoring, with results recorded for each 
participant. The location of training (country and program), years as a practicing pathologist,  
and approximate number of thyroid gland surgical cases diagnosed per year were recorded. The 
degree of agreement between participants was assessed by kappa statistics, using the individual 
criteria and the average, composite scores of the Working Group as a point of comparison.  
Results: Using the Nuclear Standardized Scoring System, the interobserver agreement for final 
diagnosis score was generally excellent: unweighted and weighted kappa values between 
individual observers ranging from 0.242 to 0.930 (average 0.626). There was significant 
agreement between observers in reaching an interpretation of the presence or absence of nuclear 
features to diagnose NIFTP (score 0-1 versus score of 2-3), with California pathologists, 0.63 
(median 0.66, SD 0.15), Japanese pathologists, 0.64 (median 0.66, SD 0.16) and UK 
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pathologists, 0.60 (median 0.57, SD 014) compared to the expert panel, 0.70 (median 0.73, SD 
0.19).  
Conclusions:  Use of the nuclear scoring system to evaluate the nuclear features of papillary 
thyroid carcinoma as applied to reach the diagnosis of NIFTP shows a good to substantial 
interobserver agreement, suggesting consensus can be reached in diagnosing the nuclear features 
required for this newly reclassified tumor.  
 
Key Words: Thyroid neoplasms; Thyroid cancer, papillary; Carcinoma, papillary 
follicular/pathology; consensus; observer variation; scoring system; humans 
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INTRODUCTION 
Papillary thyroid carcinoma (PTC) is the most common malignant neoplasm of the thyroid gland 
worldwide, usually associated with an excellent survival. Recently, “The Endocrine Pathology 
Society Conference for Re-examination of the Encapsulated Follicular Variant of Papillary 
Thyroid Cancer” convened March 20-21, 2015 in Boston, MA, and based on extensive 
evaluation of cases, outcome data and the development of a set of specific inclusion and 
exclusion criteria, issued a new  name for this entity: Noninvasive follicular thyroid neoplasm 
with papillary-like nuclear features (NIFTP).1 During discussion by the 24 member experts, the 
notion of criteria reproducibility, specifically as it relates to the nuclear features of PTC was a 
major concern. Previous studies have shown considerable interobserver and intraobserver 
variability among experts in the diagnosis of the cytomorphonuclear features of papillary 
carcinoma in follicular variant tumors,2, 3 with a range from 17 to 100%. Only 1 of 15 cases 
achieved unanimous agreement in one such review,2 while concordance was achieved in 39% in 
another.3 Thus, there seems to be a need to validate the nuclear features of PTC, perhaps 
including a hierachy of importance, and a qualitative assessment of these features in order to be 
reproducible, and hence achieve a more precise and potentially accurate overall diagnosis.  
Towards this end, only the nuclear features of PTC were examined in this validation, while the 
other architectural and cellular findings were not included (these criteria include: invasion, 
follicular architecture, papillae, psammoma bodies, necrosis, mitotic activity, encapsulation, 
colloid tincture, fibrosis and multinucleated giant cells or crystalloids). Specifically, the tumors 
showed a follicular pattern without papillae identified, so that architectural findings could not 
bias interpretation of the cytomorphonuclear features. Further, no minimum quantitative area 
within a tumor that showed nuclear features of PTC was established. One author has used at least 
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3 high power fields showing nuclear features of PTC per 3 mm of tumor diameter to establish 
bone fide nuclear features,4 but this quantitation has not been tested. The are many 
cytomorphonuclear features of papillary carcinoma (Table 1). In discussion during the 
aforementioned consensus conference, nuclear alterations seem to get the most weighting by 
pathologists as they evaluate a case, but varying thresholds by each individual in application to 
an individual case, results in significant diagnostic variation.  A standardized group of 3 major 
categories were defined by the consensus conference expert panel (Table 2), creating a binary 
“present” or “absent” value, and an assigned score of 0 or 1 for each major category. Therefore, 
nuclear size and shape; nuclear membrane irregularities; and nuclear chromatin characteristics 
are the three nuclear categories, with one point assigned if interpreted to be present. Overall, if 
there is a score of 2 or 3, then the nuclear features of PTC are sufficiently well developed as to 
be diagnostic (in whatever category tumor applied). 
To validate and test the Nuclear Standardized Scoring System for papillary carcinoma nuclear 
features, cases were evaluated by general practicing pathologists in the United States, Japan and 
the United Kingdom (UK). The scores were then compared to the consensus conference experts, 
using individual scores, average scores and aggregates scores to determine a kappa 
reproducibility score.    
MATERIALS AND METHODS 
The same set of 30 images used to initially develop and then ultimately revalidate the Nuclear 
Standardized Scoring System for papillary carcinoma nuclear features by the 24 members of the 
expert panel was used to test the reproducibility by general practicing surgical pathologist (see 
eTable 5 of Nikiforov, et.1). One pathologist was excluded at his request at the time of 
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publication, and one pathologist did not rescore the validated criteria, but the original recorded 
data was still employed in the kappa statistic evaluation.  
The nuclear features of papillary carcinoma were grouped into 3 categories (Table 2): 
(1) nuclear size and shape: nuclear enlargement, elongation, overlapping and crowding (Figure 
1);  
(2) nuclear membrane irregularities: irregular contours, nuclear grooves, nuclear folds, 
intranuclear cytoplasmic pseudoinclusions (Figure 2); and  
(3) nuclear chromatin characteristics: chromatin clearing, margination to the membranes, glassy 
nuclei and fine even delicate chromatin (Figure 3). 
A 3-point scoring scheme assigned each class of nuclear features a score of 0 or 1, with a range 
of scores from 0 to 3.  Based on a mutation positive endpoint serving as the reference standard 
for the original test set (n=18 cases with molecular testing) 1, a score of 0 or 1 was considered 
inadequate for the diagnosis of NIFTP (i.e. benign), while a score of 2 or 3 was considered 
sufficient for the diagnosis of NIFTP (see supplemental table 1 for additional information). The 
same visual guide used by the expert panel (see eFigure 4 of Nikiforov, et.1) was included at the 
start of the evaluation. 
An invitation to participate was extended to 30 general surgical pathologists in California 
(United States of America), Japan and the United Kingdom (UK) by the authors (LDRT, KK, 
DNP).  
The instructions were as follows:  
1) Study the teaching module, highlighting the inclusion and exclusion criteria for the 
diagnosis (about 45-60 minutes); 
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2) Attempt to review the 30 cases in one or two seatings (i.e., over a short interval, 
estimating 30 minutes to complete); 
3) Enter a score of “0” or “1” for each category; 
4) Provide demographic data, including years of experience and volume of work; 
5) Aggregated and individual results will be compared to the 24 endocrine expert 
pathologists for statistical evaluation of reproducibility; 
A 72-page training module (PDF) was distributed with the invitation (an expanded version can 
be viewed via: DOI: 10.13140/RG.2.1.2063.9124), along with a spreadsheet that included the 
case number and 3 columns in which to score the three nuclear feature categories (Table 2). The 
“total score” was automatically calculated using the standard Excel spreadsheet sum function. 
Additional recorded data included the number of whole years as a practicing pathologist (post 
training), residency training program attended, fellowship training and/or certification, board 
certification and/or additional board certification, and a reasonable approximation of total 
number of thyroid surgical pathology cases diagnosed/signed out per year.   
Completed spreadsheets were received from 21 pathologists in the greater Southern California 
region, 30 pathologists in Japan, and 26 pathologists from the UK, which comprised the basis for 
all further analysis. Each groups’ demographics are summarized in Table 3. A few explanatory 
notes regarding the demographics are highlighted in supplemental Table 2 for sake of 
completeness.  
Previously published molecular data served as the reference standard to fit a random-
effects logistic regression model to predict molecular diagnosis based on molecular status and 
individual pathologist’s nuclear score as previously described 1. The logistic model accounted for 
correlation among pathologists evaluating the same case.  Based on prior validation {Nikiforov, 
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2016 #6064, score 0-1 was used to identify mutation-negative and score 2-3 mutation-positive 
lesion.  
The received data were also analyzed using a kappa statistic (McNemar statistic) for all 
30 cases for each of the 24 expert pathologists, and each of the individual pathologists from each 
of the 3 geographic regions, including calculation of a super kappa (weighted Kappa). Mean, 
median, range and standard deviation was calculated for each group. Kappa statistics were also 
calculated for each of the criteria for the experts and well as for each participant, with averages, 
medians and standard deviations. A super kappa was calculated as a sum of the numerators of the 
individual kappas divided by the sum of the denominators of the individual kappas for each 
reviewer as a form of weighted kappa. The results were based on comparing each reviewer to the 
expert consensus for each criteria and also for the overall diagnosis, while the experts were also 
compared to their own consensus. Standard commercial available software (statistical package 
for the social sciences, SPSS) was used for these calculations, using confidence intervals of 95% 
for all positive findings and an alpha level set at p<0.05. 
The kappa statistic (kappa coefficent) uses 1 to indicate perfect agreement and 0 indicating 
agreement by pure chance alone. The following kappa statistics are used for interpretation in this 
paper:  
Kappa  Agreement 
0.01-0.20 Slight agreement 
0.21-0.40 Fair agreement 
0.41-0.60 Moderate agreement 
0.61-0.80 Substantial agreement 
0.81-0.99 Almost perfect agreement 
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RESULTS 
Each pathologist from each geographic region provided a 0 or 1 value for each of the 3 nuclear 
categories. For example, a reference of normal, uninvolved adjacent thyroid gland parenchyma 
from the same slide captured at the same magnification was provided (Figures 4-6), while a 
single, representative high power field (20x magnification) using an Aperio scanned digital 
image from 30 different cases were included for review. These were the same cases reviewed by 
the expert panel, although the images included in this publication are unique from those already 
published, included for illustrative purposes only.  
The overall average score for each case by geographic region (Table 4) was calculated, showing, 
on average, a substantially similar result for each case between the individual groups when 
compared to the experts. The UK pathologists scored cases with an overall lower average total 
score than the experts, Californian or Japanese pathologists. As each case was individual, a 
standardized mean could not be achieved, but suffice it to say there was an overall bias towards a 
lower total score among UK pathologists.  
Across all pathologists, utilizing 0 or 1 to be diagnostic of a benign nodule and a score of 
2 or 3 to be diagnostic of NIFTP, the nuclear scoring system demonstrated: a sensitivity of 
75.0% (95% CI, 72.2%-77.6%), specificity of 76.9% (95% CI, 72.4%-80.8%), and overall 
accuracy of 75.5% (73.2%-77.7%).  The accuracy of the model was not significantly influenced 
by country, years of experience or number cases seen.  However, the UK pathologists trended 
towards lower accuracy, while there was a very slight trend towards improved accuracy with 
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increased experience and number of cases (see supplemental Table 3, and supplemental Figures 
1, and 2). 
Overall, a kappa statistic was rendered for each of the individual criterion and as a 
predictor of final diagnosis (Table 5), with a super kappa calculated as a weighted average. 
Again, the UK pathologists tended to show a lower overall mean score for each criterion, with 
the first criterion (nuclear size and shape) the most likely to be difficult to achieve a meaningful 
kappa statistic. However, when all three criteria were aggregated to achieve a final diagnosis 
score (either 0/1 or 2/3 total score), then a substantial agreement was achieved, with a kappa 
statistic from 0.6 to 0.64 for the general surgical pathologists in comparison to 0.70 for the expert 
pathologists. The super kappa statistic yielded a kappa of 0.55 to 0.56 in comparison to 0.61 for 
the experts, again a finding that showed moderate to substantial agreement. Overall, the bin 
midpoint kappa values suggested a good to substantial agreement (Table 6) for each of the 
geographic areas, a finding that was similar to the results for the experts. When compared as 
overall kappa statistics between the regions, there was significant reproducibility (Figure 7).  
DISCUSSION 
This validation study has demonstrated a reasonable likelihood that general surgical pathologists 
will be able to apply the criteria of the NIFTP Nuclear Standardized Scoring System to an 
individual case and achieve a result that is in good to substantial agreement with expert 
pathologists. Reproducibility is important in the ability to apply specific criteria, and that was the 
main aim of this validation. Thus, the remaining criteria (invasion, patterns of growth, area of 
tumor with the nuclear features of PTC) were not evaluated in this cohort.  
Accuracy of the previously established cut-off using the cases in this set with molecular 
results as a reference standard as previously calculated appears to be somewhat lower as 
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compared to that of the original expert scoring {Nikiforov, 2016 #6064}. This is not an entirely 
unexpected, since in addition to “expertise,” the expert group was additionally primed repeatedly 
over the course of several months by continued teleconferences and thus visual repetition of 
specific nuclear features that likely improved standardization of thresholds within the group.  
Even with a diagnostic accuracy of ~75% when extending to this international group of 77 
pathologists, the performance of this scoring system is still improved from the historical 
precedent in prior (albeit smaller) studies of follicular patterned lesions 2.  Thus even with some 
deprecation from the accuracy of the original expert group, the performance of the nuclear 
scoring system is still favorable.   
Neither, number of years in practice, number of cases reviewed, nor location significantly 
factored into the accuracy of the model.  However, as expected, there is slight a trend towards a 
higher number of cases (experience) per year and a higher number of years in practice being 
correlated to being able to recognize the nuclear features with greater consistency and 
reproducibility, and thus “accuracy” in final diagnosis. However, the estimated number of cases 
is fraught with bias, and the exact number of years in practice versus years of specialization or 
years post training is different for each of the locales. Interestingly, there is a trend towards 
reduced scoring by the UK pathologists. It is well known that there is geographic variation in 
applying thresholds for follicular patterned lesions 3, 5. UK and European pathologists have an 
overall different training and threshold for the interpretation of the nuclear features of papillary 
carcinoma, and thus this lower scoring is to be expected. However, when tasked with reviewing 
the education module before scoring, there may be a change or increase in scoring. This trend 
will be open to further discussion as greater experience with the diagnostic term and its 
application is developed.  
  Thompson / Validation of Nuclear Scoring for NIFTP / 13 
It seems that with education and experience, “The Endocrine Pathology Society Conference for 
Re-examination of the Encapsulated Follicular Variant of Papillary Thyroid Cancer” criteria for 
scoring the nuclear features considered diagnostic of papillary-like nuclear features can be 
applied with reproducibility and yield similar diagnostic results between experts and general 
practicing pathologists for the newly reclassified Non-invasive follicular thyroid neoplasm with 
papillary-like nuclear features (NIFTP). 
CONCLUSION 
There is good to substantial agreement between general surgical pathologists around the globe 
and expert endocrine pathologists in achieving reproducible Nuclear Standardized Scoring 
System for papillary carcinoma nuclear features total scores for the classification of the nuclear 
features of papillary carcinoma. This NIFTP Nuclear Standardized Scoring System can thus be 
applied with confidence in approaching thyroid gland nodules or tumors in attempting to yield a 
reproducible result between independent reviewers of these nuclear features. 
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TABLES 
Table 1: Cytomorphonuclear Features of Papillary Thyroid Carcinoma. 
Enlarged cells (compared to adjacent parenchyma) 
Increased (high) nuclear to cytoplasmic ratio 
Nuclear enlargement 
Nuclear overlapping 
Nuclear crowding (high cellularity) 
Nuclear elongation 
Irregular nuclear placement within the cell (luminal, mid or basal) 
Nuclear grooves or folds 
Nuclear contour irregularities (demi-lunes, rat-bites) 
Intranuclear cytoplasmic psuedoinclusions 
Pale, fine delicate nuclear chromatin distribution 
Nuclear chromatin clearing (Orphan Annie nuclei) 
Nuclear chromatin margination/condensation at the periphery 
Prominent nuclear membranes 
Multiple nucleoli 
Nucleoli identified on the nuclear membrane 
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Table 2:  Nuclear Features of Papillary Thyroid Carcinoma Scoring Criteria.* 
 
Nuclear features (1 point each) Criteria 
1. Size and shape Enlargement, elongation, crowding, overlapping 
2. Membrane irregularities Irregular contours, grooves, folds, intranuclear 
cytoplasmic inclusions 
3. Chromatin characteristics Chromatin clearing, margination to the nuclear 
membranes, glassy nuclei, fine-even delicate chromatin 
Score: 0: absent or only slightly expressed 
1: present or well developed 
Total score: 0 or 1: Not diagnostic 
2 or 3: Diagnostic of papillary thyroid carcinoma nuclei 
*Modified from Nikiforov, et. al. 1 
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Table 3:  Demographics of General Surgical Pathologists 
 
Characteristic 
United 
States of 
America 
Japan 
United 
Kingdom 
Total Number 21 30 26 
Years of practice:    
     Range 1 – 36 1 – 31 1 – 41 
     Mean 13.6 15.6 14.9 
     Median   10.0 14.5 15.0 
Number of unique residency training programs 13 n/a 7 
Fellowship or additional training 16 28 8 
     Cytology 5 28 6 
     Surgical Pathology 4 n/a 2 
     Other 7 n/a n/a 
Board certification 21 30 20 
Estimated/actual annual number of thyroid cases    
     Range 6 – 69 5 – 150 10 – 300 
     Mean 20.2 37.5 96.9 
     Median 14 30 67.5 
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Table 4:  Overall Mean Score for Each Case by Geographic Group Compared to the 
Expert Panel 
 
Case # Experts USA Japan UK 
A8 2.958 3.000 2.800 2.731 
A26 2.500 2.762 2.600 2.192 
A27 2.042 1.952 2.000 1.462 
A29 1.125 1.286 1.300 1.385 
A35 2.708 2.476 2.633 2.423 
A36 2.375 1.619 1.967 1.692 
A37 0.083 0.000 0.133 0.115 
A38 1.625 1.524 1.267 1.538 
A41 1.208 1.000 0.800 0.962 
A43 1.125 0.952 0.867 0.500 
A46 0.667 0.476 0.400 0.077 
A47 0.792 1.143 1.133 0.731 
A52 0.167 0.048 0.100 0.154 
A56 1.042 0.619 0.800 0.423 
A58 1.333 1.238 1.367 1.077 
A59 2.167 2.238 2.033 1.923 
A60 0.000 0.333 0.167 0.115 
A62 2.708 2.810 2.600 2.615 
A73 2.750 2.810 2.467 2.577 
A79 2.292 2.143 2.133 1.577 
A80 0.708 0.952 0.667 0.423 
A102 3.000 2.952 2.767 3.000 
A111 2.792 3.000 2.733 2.846 
A120 1.750 1.810 1.367 0.923 
A121 0.542 0.429 0.600 0.269 
A126 2.792 2.667 2.333 2.269 
A127 2.833 2.381 2.400 2.385 
A128 2.583 2.571 2.333 2.231 
A134 2.083 2.095 2.067 1.962 
A136 1.917 1.905 1.533 1.192 
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Table 5:  Kappa Statistic for Individual Criteria and Final Diagnosis between Groups and 
the Experts 
 
Kappa Statistic Values Experts California Japan UK 
Kappa for 1st 
Criterion 
Median 0.60 0.47 0.48 0.44 
Mean 0.54 0.49 0.41 0.44 
St. Dev 0.19 0.15 0.20 0.14 
Kappa for 2nd 
Criterion 
Median 0.67 0.61 0.67 0.66 
Mean 0.61 0.60 0.63 0.65 
St. Dev 0.26 0.15 0.21 0.19 
Kappa for 3rd 
Criterion 
Median 0.67 0.61 0.60 0.59 
Mean 0.68 0.60 0.59 0.57 
St. Dev 0.14 0.16 0.2 0.16 
Kappa for final 
diagnosis (score of 
0/1 vs 2/3) 
Median 0.73 0.66 0.66 0.57 
Mean 0.70 0.63 0.64 0.60 
St. Dev 0.19 0.15 0.16 0.14 
Super Kappa 
Median 0.64 0.60 0.57 0.55 
Mean 0.61 0.56 0.55 0.55 
St. Dev 0.13 0.09 0.12 0.11 
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Table 6: Kappa Value Bin Midpoints by Regional Pathologists 
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Table 7: All Kappa Values Counts by Regional Pathologists 
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FIGURE LEGENDS 
Figure 1: The cells are enlarged, with a very high nuclear to cytoplasmic ratio, showing 
greatly enlaraged nuclei, showing elongation and overlapping (case A102). 
Figure 2: The nuclei show contour irregularities, nuclear folds and nuclear grooves (cases 
A102 and A008, left and right respectively). 
Figure 3: Nearly all of the nuclei in this field show optical clearing, with margination of the 
nuclear chromatin towards the periphery (case A111). 
Figure 4: Case A008. The inset shows the size of the normal cells and nuclei. This case had 
an overall average nuclear score of 2.844, well above the 2 cutoff for nuclear features of 
papillary carcinoma.  
Figure 5: Case A037. The inset shows the size of the normal cells and nuclei. This case had 
an overall average nulcear score of 0.083, a total score interpreted to be benign. 
Figure 6: Case A111. The inset shows the size of the normal cells and nuclei. This case had 
an overall average nuclear score of 2.86, a total score intepreted to represent papillary 
nuclear features. 
  Thompson / Validation of Nuclear Scoring for NIFTP / 23 
SUPPLEMENTAL TABLE 1 
For modeling purposes in the original evaluation, using a molecular end point as the reference 
“gold standard” separating NIFTP from benign conditions, the scoring scheme achieved the most 
accurate classification when a score of 0 or 1 was diagnostic of a benign nodule (mutation 
negative, n=5) and a score of 2 or 3 was diagnostic of NIFTP (mutation positive, n=13). 
 Sensitivity - 86.5% (82.7% - 90.3%) 
 Specificity - 80.8% (73.8% - 87.9%) 
 PPV - 92.2% (89.1% - 95.2%) 
 NPV - 69.8% (62.2% - 77.4%) 
 Classification Accuracy - 85.0% (82.8% - 90.3%) 
Note:  Three of the expert pathologists had scores that were consistently higher with respect to 
the overall mean, and two pathologists had identical scores for all cases evaluated, a bias perhaps 
accounted for by joint review. 
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SUPPLEMENTAL TABLE 2 
The participants were asked to estimate the number of surgical pathology thyroid cases they 
signed-out/rendered a diagnosis on each year. Respondents from Japan and the UK had their 
clinical practice in a community hospital, a regional medical center, a referral center or an 
academic center, while all of the California participants were in a community practice setting.  
For California participants: 
• The exact number of surgical pathology thyroid gland cases was retrieved from a 
centralized surgical pathology reporting database (CoPath) 
• The average estimated number was 29.4, while the actual average number was 20.2 cases 
per pathologist per year indicative of a marked bias to over-estimation of the actual 
number of cases reviewed 
• A similar extrapolation may apply to the other cohorts and serves as a limitation 
For UK participants: 
• The Royal College of Pathologists in Cellular Pathology (FRCPath) exam is equivalent to 
the American Board of Pathology Certification.   
• Most of the respondents for the UK were either more interested in or experienced in 
endocrine organ pathology, as 20 or the 26 respondents were members of the UK 
Endocine Pathology Society. Pathologists are referred to as specialists when they 
have additional training, but official registration only started in 1996, and thus official 
records cannot substantiate personally provided data.  
• True years of experience versus years of practice may be skewed for various reasons. 
1. Initial responses from UK pathologists included training (cellular pathology training is 
equivalent to anatomic pathology residency in the USA and is about 5-6 years on 
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average), which was not done for the other groups. Thus, this figure had to be clarified 
and reduced accordingly. 
2. Further, specialist registration was voluntary initially, and some pathologists never 
registered. 
3. Foreign graduates are handled unique to the country where training was obtained: 
European Union countries have specialization data entered effective from the date of 
specialization in their home country, but consultants who immigrated from Asia or the 
Middle East have to apply to the UK General Medical Council with the date of specialist 
accredidation recorded only from the point of application forward. 
For Japanese and UK participants 
Actual case count may be skewed for several reasons. 
1. Pathologists in Japan and the UK routinely show thyroid gland cases to other members of 
their department or associated hospitals, and as such, the actual number of specimens 
reviewed is different from cases signed out or co-signed, potentially accounting for the 
significantly higher case load for the UK pathologists than the other groups.  
2. In addition, some pathologists review a higher number of thyroid gland cases as a result 
of second-read or external referral of the patient to a new hospital/region, and local 
custom dictates a review of all surgical pathology material before additional treatment is 
implemented locally. 
3. Finally, there is an increasing trend towards subspecialist practice, especially in the UK, 
where a selected person(s) at the cancer center reviews all thyroid gland cases, not only 
for their own patients, but also for local-regional hospitals or cancer centers; thus, one 
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thyroid gland case may be reviewed by up to 5 pathologists, all of whom count it as a 
case diagnosed.  
Regarding designation as an expert 
 Expert designation is highly subjective 
 However, definitive separation of an “expert pathologist” from a pathologist with 
significant years of experience or a high volume (>200 cases per year) practice cannot be 
reliably determined. Referral or second opinion consultation cases in endocrine organ 
pathology sent to a specific individual who has a significant publication and teaching 
record would qualify the person as an expert; these criteria were not definitively met by 
the participants in study. 
 While not a significant factor, a few of the respondents (up to 5) may have published in 
endocrine organ pathology, although without a significant publishing track record (i.e., 
more than 2 publications per year in a peer reviewed Medline indexed journal) or major 
education role (lecturing or teaching on endocrine organ pathology for medical students, 
residents or practicing pathologists at regional, national or international venues).  
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SUPPLEMENTAL TABLE 3 
Validation of all 77 observers from each country using 0 or 1 to be diagnostic of a benign nodule 
and a score of 2 or 3 to be diagnostic of NIFTP was as follows: 
 Sensitivity - 75.0% % (72.2%-77.6%) 
 Specificity – 76.9% (72.4% - 80.8%) 
 PPV – 89.4% (87.1%-91.3%) 
 NPV – 54.2% (50.0%-58.3%) 
 Classification Accuracy – 75.5% (73.2% - 77.7%) 
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SUPPLEMENTAL FIGURE 1 
Mean case score with 95% confidence interval by individual pathologist for cases in the training 
set.   The red horizontal line is the grand mean across all cases and all pathologists.  Many UK 
pathologists are well below the mean.  
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SUPPLEMENTAL FIGURE 2 
Diagnostic accuracy as a function of country and experience.  No parameter was significant, but 
UK pathologists show lower accuracy, and both number of cases and years in practice do appear 
to improve accuracy, albeit marginally. 
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